# Jain 116‚Üí86 Breakthrough Analysis

**Date**: 2025-11-03
**Status**: ‚úÖ Mathematical impossibility confirmed | üéØ Two viable paths identified

---

## üö® THE CORE PROBLEM

**Starting point**: 116 ELISA-only antibodies (94 specific / 22 non-specific)
**Target**: Novo's 86 antibodies (59 specific / 27 non-specific)

**Mathematical reality**:
```
To go from 22 ‚Üí 27 non-specific by REMOVAL ALONE is IMPOSSIBLE.
You cannot ADD 5 non-specific antibodies by removing antibodies.
```

**This proves Novo either:**
1. Reclassified labels (ELISA=0 ‚Üí non-specific based on other criteria)
2. Used different ELISA threshold (‚â•3 instead of ‚â•4)
3. Imported antibodies from outside the 116 pool
4. Had different ELISA data than Max's private file

---

## üßÆ THE MATH

### Simple Removal Scenario (FAILS)
```
Start:  94 specific + 22 non-specific = 116
Remove: 35 specific +  ? non-specific = 30 total
Target: 59 specific + 27 non-specific = 86

Math check:
  94 - 35 = 59 ‚úì
  22 - ? = 27  ‚ùå Need to REMOVE -5 (ADD 5!)
```

**Conclusion**: Simple removal CANNOT work.

### Reclassification Scenario (WORKS!)
```
Start:  94 specific + 22 non-specific = 116

Step 1: Reclassify 5-7 ELISA=0 ‚Üí non-specific
  After: 89 specific + 27 non-specific = 116

Step 2: Remove 30 specific antibodies
  Final: 59 specific + 27 non-specific = 86 ‚úì
```

**Conclusion**: This is the ONLY way to hit Novo's distribution!

---

## üìä TWO VIABLE APPROACHES

### Approach A: Biology-First QC (Method-Faithful)

**By: Assistant's deterministic pipeline**

**QC Rules** (applied sequentially):
1. **QC-1a**: Drop if no plausible VH CDR-H3 anchors (C‚Ä¶W)
2. **QC-1b**: Drop VH/VL length outliers (|z|‚â•2.5)
3. **QC-2a**: Drop CDR-H3 pathologies (length <5 or >26, |z|‚â•2.5)
4. **QC-3**: Drop charge extremes (|total_charge_z|‚â•2.5)
5. **QC-5**: Tiebreaker removal (objective ranking)

**Results**:
```
Removed 30 antibodies:
  - cixutumumab (VH length outlier)
  - muromonab (CDR-H3 pathology)
  - lenzilumab (charge extreme)
  - 27 via tiebreaker (all ELISA=0)

Final: 86 antibodies = 66 specific / 20 non-specific
```

**Distribution**: 66/20 (NOT 59/27)

**To match Novo's 59/27**, apply "parity shim":
- Reclassify 7 ELISA=0 ‚Üí non-specific:
  - ganitumab, gemtuzumab, panitumumab, tigatuzumab, girentuximab, efalizumab, zanolimumab
- Final: 59 specific / 27 non-specific ‚úì

---

### Approach B: ELISA+Biophysics Reclassification (Our Hypothesis)

**By: Our z-score + flag analysis**

**Reclassification candidates** (ELISA=0 with other red flags):
```
7 candidates with ELISA=0 but total_flags‚â•3:
  - bimagrumab (total=4)      ‚Üê Top candidate!
  - atezolizumab (total=3)
  - eldelumab (total=3)
  - glembatumumab (total=3)
  - infliximab (total=3)
  - rilotumumab (total=3)
  - seribantumab (total=3)
```

**Scenario**:
```
Start: 94 specific + 22 non-specific = 116

Step 1: Reclassify 5 of the 7 ‚Üí non-specific
  After: 89 specific + 27 non-specific = 116

Step 2: Remove 30 specific via QC
  - 21 from our QC candidates (z-score analysis)
  - 9 more specific antibodies
  Final: 59 specific + 27 non-specific = 86 ‚úì
```

---

## üî¨ COMPARISON: Two Approaches

| Aspect | Biology-First (Assistant) | ELISA+Biophysics (Us) |
|--------|---------------------------|------------------------|
| **Method** | Sequence/biophysics QC first | Reclassify then remove |
| **Reclassified** | 7 (parity shim) | 5 (hypothesis) |
| **Removed** | 30 (deterministic) | 30 (21 identified + 9 TBD) |
| **Distribution** | 66/20 ‚Üí 59/27 (shim) | 59/27 (direct) |
| **Overlap with our reclass** | 0 of 7 | 5 of 7 |
| **Reproducible** | ‚úÖ Fully scripted | ‚ö†Ô∏è Partial (need 9 more) |

---

## üéØ KEY FINDINGS

### 1. **No Overlap Between Removal and Reclassification**

**Our analysis**:
- 7 reclassification candidates (ELISA=0, total‚â•3)
- 8 removal candidates (VH outliers + clinical issues)
- **0 overlap** ‚úì

**Assistant's analysis**:
- 7 parity flip candidates (for 59/27 match)
- 30 removed antibodies (biology-first QC)
- **0 overlap with our reclass candidates** (but 3 overlap with removals)

### 2. **Three Antibodies Removed by Assistant, Reclass by Us**

```
bimagrumab      - ELISA=0, total=4
glembatumumab   - ELISA=0, total=3
infliximab      - ELISA=0, total=3
```

**Interpretation**: These could go either way:
- **Remove** if you prioritize sequence/biophysics purity
- **Reclassify** if you want to keep them as non-specific examples

### 3. **Different Parity Flips**

**Assistant's 7 parity flips** (deterministic tiebreaker):
```
ganitumab, gemtuzumab, panitumumab, tigatuzumab,
girentuximab, efalizumab, zanolimumab
```

**Our 7 reclass candidates** (ELISA=0 + other flags):
```
bimagrumab, atezolizumab, eldelumab, glembatumumab,
infliximab, rilotumumab, seribantumab
```

**No overlap!** This suggests multiple valid paths to 59/27.

---

## üìÅ DELIVERABLES FROM ASSISTANT

| File | Description |
|------|-------------|
| `features_116.csv` | All features + z-scores |
| `qc_removed_30.txt` | 30 IDs removed via biology-first QC |
| `jain_ELISA_ONLY_86_biology_first.csv` | 86 antibodies (66 spec / 20 nonspec) |
| `jain_ELISA_ONLY_86_parity_shim.csv` | 86 antibodies (59 spec / 27 nonspec via shim) |
| `audit_log.json` | Full QC audit trail |
| `report.md` | Summary narrative |

---

## üöÄ RECOMMENDED PATH FORWARD

### Option 1: Use Biology-First 66/20 as Primary (Method-Faithful)
```
‚úÖ Fully reproducible
‚úÖ No arbitrary reclassification
‚úÖ Defensible QC rules
‚ùå Doesn't match Novo's 59/27
‚ùå Can't directly compare confusion matrix
```

**Use when**: You want to be method-faithful to ELISA-only + sequence QC

### Option 2: Use Parity Shim 59/27 as Secondary (Novo-Comparable)
```
‚úÖ Matches Novo's distribution
‚úÖ Allows direct confusion matrix comparison
‚úÖ Documented which 7 were flipped
‚ùå Requires justifying the 7 flips
‚ùå Not purely ELISA-based anymore
```

**Use when**: You want to compare directly to Novo's reported metrics

### Option 3: Report BOTH + Document Discrepancy
```
Primary:   86 antibodies (66/20) - biology-first, method-faithful
Secondary: 86 antibodies (59/27) - parity shim for Novo comparison
Document:  "Novo's 59/27 distribution requires either (a) reclassification
            of 7 ELISA=0 antibodies OR (b) different source pool"
```

**Use when**: You want maximum transparency and comparability

---

## üéØ NEXT STEPS

### Immediate Actions
1. ‚úÖ **Document the mathematical impossibility** (this file)
2. ‚úÖ **Compare assistant's deliverables with our analysis**
3. ‚è∏Ô∏è **Decide**: Use 66/20, 59/27, or both?
4. ‚è∏Ô∏è **Email Max/Jain**: Ask for clarification on 116‚Üí86 methodology

### For Inference
1. **Run on 66/20 set** (biology-first, no shim)
2. **Run on 59/27 set** (parity shim applied)
3. **Compare both to Novo's [[40, 19], [10, 17]]**
4. **Report which matches better** + document why

### For Publication
1. **Supplement A**: Biology-first 66/20 (primary, method-faithful)
2. **Supplement B**: Parity shim 59/27 (secondary, Novo-comparable)
3. **Main text**: Document the 22‚Üí27 impossibility and the two paths

---

## üí° BREAKTHROUGH INSIGHTS

### 1. **The 5-Antibody Shift is the Smoking Gun**
Going from 22‚Üí27 non-specific proves Novo did NOT just remove antibodies.
They either reclassified, used different thresholds, or had different data.

### 2. **Multiple Valid Paths to 59/27**
Both approaches (ours and assistant's) can hit 59/27, but via different antibodies.
This suggests the exact 7 flips are somewhat arbitrary without Novo's criteria.

### 3. **Biology-First QC is Rock Solid**
The 66/20 result is fully defensible and reproducible.
It's a valid test set regardless of whether it matches Novo exactly.

### 4. **Parity Shim is Transparent**
Rather than hiding the reclassification, assistant explicitly separates:
- `label` (ELISA-faithful)
- `label_parity_shim` (flipped for 59/27 match)

This is best practice for reproducibility!

---

## üìä SUMMARY TABLE

| Metric | Start (116) | Bio-First (86) | Parity Shim (86) | Novo (86) |
|--------|-------------|----------------|------------------|-----------|
| **Specific** | 94 | 66 | 59 | 59 |
| **Non-specific** | 22 | 20 | 27 | 27 |
| **Total** | 116 | 86 | 86 | 86 |
| **Method** | ELISA-only | Seq/bio QC | +7 flips | Unknown |
| **Match Novo?** | No | No | Yes | - |

---

## ‚úÖ CONCLUSIONS

1. **Mathematical impossibility confirmed**: 22‚Üí27 nonspec requires reclassification or different data
2. **Two viable paths identified**: Biology-first (66/20) vs Parity shim (59/27)
3. **No single "correct" answer**: Without Novo's exact criteria, both are defensible
4. **Recommended**: Report both + document the discrepancy transparently

**The breakthrough**: We now understand WHY we couldn't match Novo exactly, and we have TWO principled paths forward with full reproducibility!
